vs
Apellis Pharmaceuticals, Inc.（APLS）与NOODLES & Co（NDLS）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是NOODLES & Co的1.6倍（$199.9M vs $122.1M），NOODLES & Co净利率更高（-7.5% vs -29.5%，领先22.0%），NOODLES & Co同比增速更快（-4.1% vs -5.9%），NOODLES & Co自由现金流更多（$-2.8M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -1.2%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Noodles & Company是源自美国的休闲快餐连锁品牌，主打融合多国风味及美式特色的面条菜品，同时也供应汤品和沙拉。品牌由亚伦·肯尼迪创立于1995年，总部位于科罗拉多州布鲁姆菲尔德，截至2022年年中，品牌已在美国31个州开出了458家门店。
APLS vs NDLS — 直观对比
营收规模更大
APLS
是对方的1.6倍
$122.1M
营收增速更快
NDLS
高出1.8%
-5.9%
净利率更高
NDLS
高出22.0%
-29.5%
自由现金流更多
NDLS
多$11.5M
$-14.3M
两年增速更快
APLS
近两年复合增速
-1.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $122.1M |
| 净利润 | $-59.0M | $-9.2M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | -5.2% |
| 净利率 | -29.5% | -7.5% |
| 营收同比 | -5.9% | -4.1% |
| 净利润同比 | -62.2% | 32.8% |
| 每股收益（稀释后） | $-0.40 | $-0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSNDLS
| Q4 25 | $199.9M | — | ||
| Q3 25 | $458.6M | $122.1M | ||
| Q2 25 | $178.5M | $123.8M | ||
| Q1 25 | $166.8M | — | ||
| Q4 24 | $212.5M | $122.8M | ||
| Q3 24 | $196.8M | $127.4M | ||
| Q2 24 | $199.7M | $121.4M | ||
| Q1 24 | $172.3M | $124.3M |
净利润APLSNDLS
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $-9.2M | ||
| Q2 25 | $-42.2M | $-9.1M | ||
| Q1 25 | $-92.2M | — | ||
| Q4 24 | $-36.4M | $-6.8M | ||
| Q3 24 | $-57.4M | $-13.6M | ||
| Q2 24 | $-37.7M | $-6.1M | ||
| Q1 24 | $-66.4M | $-6.1M |
营业利润率APLSNDLS
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | -5.2% | ||
| Q2 25 | -18.6% | -5.2% | ||
| Q1 25 | -50.0% | — | ||
| Q4 24 | -12.3% | -3.9% | ||
| Q3 24 | -24.0% | -9.0% | ||
| Q2 24 | -14.7% | -3.4% | ||
| Q1 24 | -36.0% | -3.7% |
净利率APLSNDLS
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | -7.5% | ||
| Q2 25 | -23.6% | -7.3% | ||
| Q1 25 | -55.3% | — | ||
| Q4 24 | -17.1% | -5.5% | ||
| Q3 24 | -29.2% | -10.7% | ||
| Q2 24 | -18.9% | -5.1% | ||
| Q1 24 | -38.5% | -4.9% |
每股收益（稀释后）APLSNDLS
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | $-0.20 | ||
| Q2 25 | $-0.33 | $-0.20 | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $-0.30 | $-0.15 | ||
| Q3 24 | $-0.46 | $-0.30 | ||
| Q2 24 | $-0.30 | $-0.14 | ||
| Q1 24 | $-0.54 | $-1.64 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $4.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $-38.9M |
| 总资产 | $1.1B | $280.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSNDLS
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | $4.7M | ||
| Q2 25 | $370.0M | $1.4M | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | $3.3M | ||
| Q3 24 | $396.9M | $1.8M | ||
| Q2 24 | $360.1M | $1.3M | ||
| Q1 24 | $325.9M | $3.0M |
总债务APLSNDLS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSNDLS
| Q4 25 | $370.1M | — | ||
| Q3 25 | $401.2M | $-38.9M | ||
| Q2 25 | $156.3M | $-13.9M | ||
| Q1 25 | $164.2M | — | ||
| Q4 24 | $228.5M | $3.7M | ||
| Q3 24 | $237.1M | $9.6M | ||
| Q2 24 | $264.3M | $21.9M | ||
| Q1 24 | $266.7M | $27.2M |
总资产APLSNDLS
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | $280.6M | ||
| Q2 25 | $821.4M | $319.4M | ||
| Q1 25 | $807.3M | — | ||
| Q4 24 | $885.1M | $340.5M | ||
| Q3 24 | $901.9M | $346.3M | ||
| Q2 24 | $904.5M | $360.4M | ||
| Q1 24 | $831.9M | $368.1M |
负债/权益比APLSNDLS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $4.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-2.8M |
| 自由现金流率自由现金流/营收 | -7.1% | -2.3% |
| 资本支出强度资本支出/营收 | 0.1% | 5.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-7.5M |
8季度趋势，按日历期对齐
经营现金流APLSNDLS
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | $4.3M | ||
| Q2 25 | $4.4M | $4.0M | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.4M | $5.8M | ||
| Q3 24 | $34.1M | $4.7M | ||
| Q2 24 | $-8.3M | $7.0M | ||
| Q1 24 | $-133.0M | $164.0K |
自由现金流APLSNDLS
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | $-2.8M | ||
| Q2 25 | $4.4M | $1.1M | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | $-1.3M | ||
| Q3 24 | — | $-4.5M | ||
| Q2 24 | $-8.4M | $-1.6M | ||
| Q1 24 | $-133.3M | $-15.2M |
自由现金流率APLSNDLS
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | -2.3% | ||
| Q2 25 | 2.5% | 0.9% | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | -1.1% | ||
| Q3 24 | — | -3.5% | ||
| Q2 24 | -4.2% | -1.4% | ||
| Q1 24 | -77.3% | -12.2% |
资本支出强度APLSNDLS
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | 5.8% | ||
| Q2 25 | 0.0% | 2.4% | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | 5.8% | ||
| Q3 24 | 0.0% | 7.2% | ||
| Q2 24 | 0.0% | 7.1% | ||
| Q1 24 | 0.2% | 12.3% |
现金转化率APLSNDLS
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
NDLS
| Food And Beverage | $119.6M | 98% |
| Franchise | $2.5M | 2% |
